Clinical Trials Browser

Withdrawn × Recurrence × Gastrointestinal × Clear all

NCT03999658 2023-05-01

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Phase 2 Withdrawn

GastrointestinalLymphoid

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Cholangiocarcinoma, Lymphoma, Extranodal NK-T-Cell

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02713984 2020-03-19

A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer

Phase 1/2 Withdrawn

BreastCNSGastrointestinalGynecologicThoracic

Breast Neoplasms, Glioma, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Stomach Neoplasms, Colorectal Neoplasms

NCT02105350 2018-02-19

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Phase 1 Withdrawn

Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Recurrence

NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Phase 4 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

NCT00386516 2017-08-01

Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer

Phase 2 Withdrawn

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Gallbladder Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Cholangiocarcinoma

NCT01095523 2017-07-02

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Phase 2 Withdrawn

GastrointestinalGynecologic

Colonic Neoplasms, Neoplasm Metastasis, Peritoneal Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms